Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Early Phase 1
1(33.3%)
3Total
N/A(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07476352Early Phase 1Not Yet Recruiting

Expansion Study of ALT001 in Patients With Multiple System Atrophy

Role: lead

NCT07495150Not ApplicableNot Yet Recruiting

Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis

Role: lead

NCT06374667Not ApplicableRecruiting

The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction

Role: lead

NCT05892822Unknown

Amyotrophic Lateral Sclerosis Registry

Role: lead

All 4 trials loaded